Coherus Oncology
CHRS
122 hedge funds and large institutions have $842M invested in Coherus Oncology in 2016 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 37 reducing their positions, and 19 closing their positions.
68.52% more ownership
Funds ownership: 0% → 68.52% (+69%)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
19% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 37
14% more capital invested
Capital invested by funds: $741M → $842M (+$101M)
4% more funds holding
Funds holding: 117 → 122 (+5)
92% less call options, than puts
Call options by funds: $268K | Put options by funds: $3.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.8M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$13.5M |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
+$11.2M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$7.17M |
| 5 |
JCG
JHL Capital Group
Chicago,
Illinois
|
+$7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.4M |
| 2 |
JP Morgan Chase
New York
|
-$10.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.78M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$5.19M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.97M |
CHRS Hedge Fund Activity: Q4 2016 in Review
122 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2016, worth a combined $842M — up 14% from $741M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CHRS positions and 19 closed out — a net gain of 6 holders — while 44 added to existing stakes and 37 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $16.8M. The largest seller was Millennium Management, cutting an estimated $13.4M.
- 122 institutional investors held Coherus Oncology (CHRS) as of Q4 2016, up from 117 in Q3 2016.
- Funds reported $842M of Coherus Oncology stock for Q4 2016, up 14% quarter-over-quarter.
- 25 funds opened new Coherus Oncology positions in Q4 2016 and 19 closed out, a net change of +6 holders.
- The largest Coherus Oncology buyer in Q4 2016 was Point72 Asset Management, an estimated $16.8M added.
- The largest Coherus Oncology seller in Q4 2016 was Millennium Management, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2016.